Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Virology|March 15, 2019
Evolution of the HIV-1 Rev Response Element during Natural Infection Reveals Nucleotide Changes That Correlate with Altered Structure and Increased Activity over TimeChringma Sherpa, Patrick E H Jackson, Laurie R Gray, et al.
Plos Pathogens|May 15, 2025
Rev-RRE activity modulates HIV-1 replication and latency reactivation: Implications for viral persistence and cure strategiesGodfrey A Dzhivhuho, Patrick E H Jackson, Ethan S Honeycutt, et al.
Open Forum Infectious Diseases|April 25, 2024
Machine Learning-based Analysis of Publications Funded by the National Institutes of Health's Initial COVID-19 Pandemic ResponseAnirudha S Chandrabhatla, Adishesh K Narahari, Taylor M Horgan, et al.
Open Forum Infectious Diseases|March 27, 2024
Analysis of National Institutes of Health Funding for the COVID-19 PandemicAdishesh K Narahari, Taylor M Horgan, Anirudha S Chandrabhatla, et al.
Medrxiv : the Preprint Server for Health Sciences|April 12, 2022
Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID 19: A Phase IIa TrialJennifer Sasson, Alexandra N Donlan, Jennie Z Ma, et al.
Open Forum Infectious Diseases|August 12, 2022
Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a TrialJennifer Sasson, Alexandra N Donlan, Jennie Z Ma, et al.
Science Immunology|February 23, 2023
Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19Bibo Zhu, Xiaoqin Wei, Harish Narasimhan, et al.
The Lancet. Respiratory Medicine|October 21, 2021
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trialAndre C Kalil, Aneesh K Mehta, Thomas F Patterson, et al.
The New England Journal of Medicine|December 11, 2020
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19Andre C Kalil, Thomas F Patterson, Aneesh K Mehta, et al.
Pageof 2